Skip to content
Subscriber Only

Genzyme’s ‘Theoretical Cure’ for MS Draws Scrutiny, Sanofi Deal

Genzyme Corp.’s experimental drug for multiple sclerosis, the treatment central to negotiations in Sanofi-Aventis SA’s $20.1 billion takeover, will profit investors only if its early promise proves true in later tests.

Genzyme says the drug, known as Lemtrada for MS and sold as Campath for leukemia, will reap peak annual sales of as much as $3.5 billion. While the medicine may meet that projection, indications of infections, thyroid complications and blood disorders may ultimately limit use, doctors say.